ICAD (ICAD) Stock Price
ICAD Price
Revenue at ICAD has contracted by 0.0% per year over the past 19 years to 19.61 M USD. For ICAD, the net margin of -28.6% is up versus -59.3% a few years ago. The consensus 12-month price target for ICAD is 3.57 USD, about 7.8% below where the stock trades today. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus.
ICAD stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
ICAD business model & stock analysis
Frequently asked questions about ICAD
ICAD Inc's business model primarily focuses on providing innovative medical solutions to enhance cancer detection and therapy planning. As a leading provider of advanced imaging and radiation therapy technologies, ICAD aims to deliver state-of-the-art solutions that enable healthcare professionals to accurately diagnose and treat patients. Their expertise lies in developing and commercializing computer-aided detection (CAD) and workflow solutions for medical imaging in specialties such as breast, lung, and colon health. With a mission to improve patient outcomes and healthcare efficiency, ICAD Inc strives to revolutionize cancer care through their cutting-edge technologies.
ICAD Inc is primarily active in the healthcare and technology industries.
The main competitors of ICAD Inc in the market include companies like Varian Medical Systems, Elekta AB, and Accuray Incorporated.
ICAD Inc is a renowned company that specializes in advanced image analysis and cancer detection technologies. With a rich history spanning several decades, ICAD Inc was founded in 1984 as a research and development firm focusing on computer-aided detection (CAD) tools for mammography. Over the years, the company expanded its portfolio, offering innovative solutions for various cancer types, including lung, colon, and prostate. With a commitment to improving patient outcomes, ICAD Inc remains at the forefront of cutting-edge medical advancements. Leveraging its expertise in artificial intelligence and machine learning, ICAD Inc continues to deliver state-of-the-art solutions for early cancer detection, contributing to the advancement of medical diagnostics.
ICAD Inc has achieved several significant milestones over the years. Some of these include the development of innovative and leading-edge solutions for advanced imaging in the healthcare industry. The company has also successfully launched its renowned ProFound AI platform, which provides invaluable assistance to radiologists in the early detection of breast cancer. Furthermore, ICAD Inc has consistently focused on expanding its global presence by forging strategic partnerships and collaborations with industry leaders. With a commitment to continuous research and development, ICAD Inc continues to revolutionize the field of medical imaging, ensuring improved patient outcomes and enhanced clinical workflows.
ICAD Inc is primarily present in the United States, with headquarters located in Nashua, New Hampshire. As a leading provider of advanced image analysis technology solutions for the healthcare industry, ICAD Inc serves customers across the United States and also has a strong presence in Europe, Asia, and other regions around the globe. With its innovative solutions and commitment to improving patient outcomes, ICAD Inc continues to expand its reach in healthcare markets worldwide.
ICAD Inc represents values of innovation, collaboration, and dedication to advanced medical imaging technology. With a strong corporate philosophy focused on enhancing patient care and improving clinical outcomes, ICAD Inc continually develops cutting-edge solutions for early cancer detection and radiation therapy. By combining their expertise in artificial intelligence and image analysis, ICAD Inc enables healthcare professionals to make more accurate diagnoses and tailor personalized treatment plans. With a commitment to continuous improvement and providing superior healthcare solutions, ICAD Inc has established itself as a trusted leader in the industry.
Analysts currently set an average price target of 3.57 USD for the ICAD stock (median: 3.57 USD), implying -7.8 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the ICAD stock: 6 recommend buying, 4 holding and 0 selling. For 2026, analysts expect ICAD to generate revenue of 22.33 M USD and earnings per share of -0.12 USD.
Converted at the current exchange rate, the ICAD share trades at 3.46 EUR (3.87 USD).
The ICAD share (ICAD) is listed on 1 stock exchanges, including: NASDAQ (ICAD).
ICAD Inc is a US-based company that has been operating in the field of medical imaging since 1984. The company's business model focuses on the development and manufacturing of advanced imaging products. ICAD offers two main product lines: iCADx and ProFound AI. iCADx is a specialized group of diagnostic products used in image analysis in radiology and brachytherapy. ProFound AI is a groundbreaking software platform specifically designed for the interpretation of digital breast tomosynthesis (DBT). The two product lines from ICAD allow doctors to obtain more accurate and faster diagnostic results. The iCADx brand offers a range of products for the treatment of breast, prostate, lung, bone, and other types of cancer. The range also includes equipment for brachytherapy, a form of radiation therapy where a radiation source is directly inserted into the body. ProFound AI is an artificial intelligence (AI)-based software platform specifically designed for breast imaging. The system uses state-of-the-art algorithms and image analysis functions to assist the doctor in the early detection and diagnosis of breast cancer. In addition, ICAD also offers professional services such as training, customer support, and technical support. These services are aimed at ensuring that the products are used optimally and achieve the highest quality of imaging and diagnosis. ICAD also operates in the research and development field. The company continuously invests in research and development to improve and further develop its products, in order to provide medical users with the best possible diagnostics. The company also actively collaborates with leading medical institutions, research organizations, and other companies to drive collaborative projects and innovation in the field of medical imaging. In conclusion, it can be said that ICAD's business model is based on state-of-the-art medical imaging technology that improves diagnosis in medical practice. ICAD aims to drive further growth and expansion of the company by constantly improving its technologies and introducing innovative products to the market.
The expected revenue of ICAD is 22.33 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of ICAD is -3.03 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of ICAD is currently -33.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ICAD stock.
The price-to-sales ratio (P/S) of ICAD is currently 4.57. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ICAD stock.
The Eulerpool Quality Score for ICAD is 1/10.
The ISIN of ICAD is US44934S2068. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of ICAD is A1J20J. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of ICAD is ICAD. The ticker symbol is used to trade ICAD shares on the stock exchange.
ICAD stock
ICAD Peer Group
ICAD Ticker
ICAD FIGI
All fundamentals and in-depth analysis of ICAD
Our stock analysis for ICAD stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ICAD. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.